New Thermoplastic Biomaterial Offers Precise Control Over Degradation and Mechanical Properties for Medical Applications

Researchers at the University of Birmingham (UK) and Duke University (USA) have engineered a novel thermoplastic polyester that allows independent control over its in‑body degradation rate and mechanical performance. The material is tailored for soft‑tissue repair and flexible bioelectronics.

Achieving a biomaterial that matches the elasticity and strength of native tissues while degrading at a clinically relevant pace is notoriously challenging. The very chemistry that imparts mechanical resilience often dictates the degradation kinetics.

The team demonstrated that incorporating succinic acid—a naturally occurring metabolite—provides a lever to fine‑tune the degradation rate.

The study, published in Nature Communications, reports that the polyester degrades steadily over four months, during which new tissue infiltrates and ultimately replaces the scaffold. In vivo tests in rats confirmed the material’s biocompatibility and safety. By modulating succinic acid content, the researchers regulated water uptake and thus the degradation pace. Importantly, the material’s engineered stereochemistry, modeled after natural rubber, decouples mechanical strength from degradation rate, allowing strength to be preserved or restored through stereochemical tuning—an unprecedented capability in degradable biomaterials.

Professor Andrew Dove of the University of Birmingham, a co‑author of the study, notes that biological tissues exhibit a wide range of elastic behaviors. “Designing synthetic substitutes that match these characteristics while also degrading in situ has long been a daunting task,” he says. “A universal solution is insufficient; our work demonstrates that implants can now be engineered with application‑specific performance profiles.”

Professor Matthew Becker of Duke, whose expertise spans chemistry, mechanical engineering, and materials science, observes that the biomaterials field has been constrained by a narrow selection of options. “Our development marks a significant leap forward,” he says. “The material’s tunability opens doors to diverse uses—from bone grafts and vascular stents to wearable electronics. We are actively pursuing further biocompatibility studies and more sophisticated demonstrations.”

Funding was provided by the National Science Foundation, the John S. & James L. Knight Foundations, the European Research Foundation, and the National Health and Medical Research Council of Australia.

The technology is also protected by international patent filings from the University of Warwick and Akron University.